You just read:

Statement from Acting FDA Commissioner Ned Sharpless, M.D. and Douglas Throckmorton, M.D., deputy center director for regulatory programs in FDA's Center for Drug Evaluation and Research, on the agency's benefit-risk framework for evaluating opioid analgesics

News provided by

U.S. Food and Drug Administration

Jun 20, 2019, 09:45 ET